Besigliptin (tosylate)

Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function[1].

Product Specifications

CAS Number

[1177460-72-8]

Product Name Alternative

SHR117887

UNSPSC

12352005

Target

Endogenous Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/besigliptin-tosylate.html

Smiles

O=S(O)(C1=CC=C(C=C1)C)=O.O=C(N2[C@@H](C[C@@H](C2)F)C#N)CN[C@@]3(C[C@]4([H])[C@@](C3)([H])CN(C4)C(N(C)C)=O)C

Molecular Formula

C25H36FN5O5S

Molecular Weight

537.65

References & Citations

[1]Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models